The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors

Endocrine Reviews

Volumn 31, Issue 4, 2010, Pages 578-599

  Ye, Lei ^a,b   Santarpia, Libero ^a,c   Gagel, Robert F ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^c ISTITUTO TOSCANO TUMORI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE; AXITINIB; CYCLOPHOSPHAMIDE; DACARBAZINE; GEFITINIB; IMATINIB; MOTESANIB; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RADIOACTIVE IODINE; SORAFENIB; SUNITINIB; TIPIFARNIB; VANDETANIB; VATALANIB; VINCRISTINE; XL 184; PROTEIN KINASE INHIBITOR; PROTEIN RET;

ABDOMINAL PAIN; ADRENAL CORTEX CARCINOMA; ALOPECIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTHRITIS; BLOATING; CARCINOID; CLINICAL RESEARCH; CLINICAL TRIAL; CONSTIPATION; CYTOTOXICITY; DEPRESSION; DIARRHEA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; ENDOCRINE TUMOR; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FATIGUE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HEART DISEASE; HOARSENESS; HORMONAL THERAPY; HUMAN; HYPERTENSION; HYPOTHYROIDISM; MOOD CHANGE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; NAUSEA; NEURAL CREST; NEUROPATHY; NONHUMAN; PANCREAS CANCER; PANCREAS ISLET CELL CARCINOMA; PANCREAS ISLET CELL TUMOR; PARAGANGLIOMA; PARESTHESIA; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; RASH; REVIEW; RHINORRHEA; SIDE EFFECT; STOMATITIS; THYROID CANCER; THYROID MEDULLARY CARCINOMA; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION; ADRENAL GLAND NEOPLASMS; ANTAGONISTS AND INHIBITORS; CARCINOID TUMOR; CARCINOMA, ISLET CELL; DRUG EFFECTS; ENDOCRINE GLAND NEOPLASMS; GENETICS; METABOLISM; PANCREATIC NEOPLASMS; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; THYROID NEOPLASMS;

ADRENAL GLAND NEOPLASMS; CARCINOID TUMOR; CARCINOMA, ISLET CELL; ENDOCRINE GLAND NEOPLASMS; HUMANS; PANCREATIC NEOPLASMS; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-RET; RECEPTOR PROTEIN-TYROSINE KINASES; THYROID NEOPLASMS;

EID: 77955393886     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/er.2009-0031     Document Type: Review

References (253)

1. Takahashi M, Ritz J, Cooper GM 1985 Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell 42:581-588 (Pubitemid 16091150)
2. Leal F, Williams LT, Robbins KC, Aaronson SA 1985 Evidence that the v-sis gene product transforms by interaction with the receptor for platelet-derived growth factor. Science 230:327-330 (Pubitemid 16225667)
3. Yarden Y, Kuang WJ, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ, Chen E, Schlessinger J, Francke U, Ullrich A 1987 Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 6:3341-3351
4. Das M, Miyakawa T, Fox CF, Pruss RM, Aharonov A, Herschman HR 1977 Specific radiolabeling of a cell surface receptor for epidermal growth factor. Proc Natl Acad Sci USA 74:2790-2794 (Pubitemid 8150822)
5. Parada LF, Tabin CJ, Shih C, Weinberg RA 1982 Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature 297:474-478 (Pubitemid 12007526)
6. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA 2002 Mutations of the BRAF gene in human cancer. Nature 417:949-954
7. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R 1997 PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275:1943-1947
8. Byström C, Larsson C, Blomberg C, Sandelin K, Falkmer U, Skogseid B, Oberg K, Werner S, Nordenskjöld M 1990 Localization of the MEN1 gene to a small region within chromosome 11q13 by deletion mapping in tumors. Proc Natl Acad Sci USA 87:1968-1972
9. Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, Latif F, Liu S, Chen F, Duh FM 1994 Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 7:85-90
10. Jijiwa M, Fukuda T, Kawai K, Nakamura A, Kurokawa K, Murakumo Y, Ichihara M, Takahashi M 2004 A targeting mutation of tyrosine 1062 in Ret causes a marked decrease of enteric neurons and renal hypoplasia. Mol Cell Biol 24:8026-8036
11. Mise N, Drosten M, Racek T, Tannapfel A, Pützer BM 2006 Evaluation of potential mechanisms underlying genotype-phenotype correlations in multiple endocrine neoplasia type 2. Oncogene 25:6637-6647 (Pubitemid 44646191)
12. Strock CJ, Park JI, Rosen DM, Ruggeri B, Denmeade SR, Ball DW, Nelkin BD 2006 Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer. J Clin Endocrinol Metab 91:79-84
13. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz M, Tufaro AP, Califano JA, Ringel MD, Zeiger MA, Sidransky D, Ladenson PW 2005 BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90:6373-6379
14. Schuchardt A, D'Agati V, Larsson-Blomberg L, Costantini F, Pachnis V 1994 Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. Nature 367:380-383
15. Lindahl M, Timmusk T, Rossi J, Saarma M, Airaksinen MS 2000 Expression and alternative splicing of mouse Gfra4 suggest roles in endocrine cell development. Mol Cell Neurosci 15:522-533 (Pubitemid 30436926)
16. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F 1993 GDNF:a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260:1130-1132 (Pubitemid 23186789)
17. Moore MW, Klein RD, Fariñ as I, Sauer H, Armanini M, Phillips H, Reichardt LF, Ryan AM, Carver-Moore K, Rosenthal A 1996 Renal and neuronal abnormalities in mice lacking GDNF. Nature 382:76-79
18. Pichel JG, Shen L, Sheng HZ, Granholm AC, Drago J, Grinberg A, Lee EJ, Huang SP, Saarma M, Hoffer BJ, Sariola H, Westphal H 1996 Defects in enteric innervation and kidney development in mice lacking GDNF. Nature 382:73-76
19. Sánchez MP, Silos-Santiago I, Frisén J, He B, Lira SA, Barbacid M 1996 Renal agenesis and the absence of enteric neurons in mice lacking GDNF. Nature 382:70-73 (Pubitemid 26243359)
20. Enomoto H, Araki T, Jackman A, Heuckeroth RO, Snider WD, Johnson Jr EM, Milbrandt J 1998 GFR α1-deficient mice have deficits in the enteric nervous system and kidneys. Neuron 21:317-324 (Pubitemid 28399692)
21. Heanue TA, Pachnis V 2007 Enteric nervous system development and Hirschsprung's disease: advances in genetic and stem cell studies. Nat Rev Neurosci 8:466-479
22. Durbec PL, Larsson-Blomberg LB, Schuchardt A, Costantini F, Pachnis V 1996 Common origin and developmental dependence on c-ret of subsets of enteric and sympathetic neuroblasts. Development 122:349-358
23. Lindfors PH, Lindahl M, Rossi J, Saarma M, Airaksinen MS 2006 Ablation of persephin receptor glial cell line-derived neurotrophic factor family receptor α4 impairs thyroid calcitonin production in young mice. Endocrinology 147:2237-2244
24. Akeno-Stuart N, Croyle M, Knauf JA, Malaguarnera R, Vitagliano D, Santoro M, Stephan C, Grosios K, Wartmann M, Cozens R, Caravatti G, Fabbro D, Lane HA, Fagin JA 2007 The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells. Cancer Res 67:6956-6964
25. Nowell PC, Hungerford DA 1961 Chromosome studies in human leukemia. II. Chronic granulocytic leukemia. J Natl Cancer Inst 27:1013-1035
26. Groffen J, Stephenson JR, Heisterkamp N, Bartram C, de Klein A, Grosveld G 1984 The human c-abl oncogene in the Philadelphia translocation. J Cell Physiol Suppl 3:179-191
27. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB 1996 Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561-566
28. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B, Goldman J, O'Brien SG, Russell N, Fischer T, Ottmann O, Cony-Makhoul P, Facon T, Stone R, Miller C, Tallman M, Brown R, Schuster M, Loughran T, Gratwohl A, Mandelli F, Saglio G, Lazzarino M, Russo D, Baccarani M, Morra E 2002 Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:645-652 (Pubitemid 34815868)
29. Ottmann OG, Druker BJ, Sawyers CL, Goldman JM, Reiffers J, Silver RT, Tura S, Fischer T, Deininger MW, Schiffer CA, Baccarani M, Gratwohl A, Hochhaus A, Hoelzer D, Fernandes-Reese S, Gathmann I, Capdeville R, O'Brien SG 2002 A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood 100:1965-1971
30. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Deininger MW, Fischer T, O'Brien SG, Stone RM, Gambacorti-Passerini CB, Russell NH, Reiffers JJ, Shea TC, Chapuis B, Coutre S, Tura S, Morra E, Larson RA, Saven A, Peschel C, Gratwohl A, Mandelli F, Ben-Am M, Gathmann I, Capdeville R, Paquette RL, Druker BJ 2002 Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99:3530-3539 (Pubitemid 34534519)
31. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, Schiffer CA, Fischer T, Deininger MW, Lennard AL, Hochhaus A, Ottmann OG, Gratwohl A, Baccarani M, Stone R, Tura S, Mahon FX, Fernandes-Reese S, Gathmann I, Capdeville R, Kantarjian HM, Sawyers CL 2002 Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99:1928-1937 (Pubitemid 34525471)
32. Joensuu H 2002 Treatment of inoperable gastrointestinal stromal tumor (GIST) with imatinib (Glivec, Gleevec). Med Klin (Munich) 97 Suppl 1:28-30
33. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA 2004 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139
34. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
35. Tuma RS 2006 Sometimes size doesn't matter: reevaluating RECIST and tumor response rate endpoints. J Natl Cancer Inst 98:1272-1274
36. 2009 SEER Cancer Statistics Review, 1975-2006. In: Horner MJ, Ries LA, Krapcho M, Neyman N, Aminou R, Howlader N, Altekruse SF, Feuer EJ, Huang L, Mariotto A, Miller BA, Lewis DR, Eisner MP, Stinchcomb DG, Edwards BK, eds. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975-2006/ (based on November 2008 SEER data submission, posted to the SEER web site)
37. Brenner H 2002 Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis. Lancet 360:1131-1135 (Pubitemid 35246487)
38. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F, Schlumberger M 2006 Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radio-iodine therapy. J Clin Endocrinol Metab 91:2892-2899
39. Elisei R, Cosci B, Romei C, Bottici V, Renzini G, Molinaro E, Agate L, Vivaldi A, Faviana P, Basolo F, Miccoli P, Berti P, Pacini F, Pinchera A 2008 Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 93:682-687
40. Husain M, Alsever RN, Lock JP, George WF, Katz FH 1978 Failure of medullary carcinoma of the thyroid to respond to doxorubicin therapy. Horm Res 9:22-25
41. Smallridge RC, Marlow LA, Copland JA 2009 Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer 16:17-44
42. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P, Wells Jr SA 1993 Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 2:851-856
43. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L 1993 Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363:458-460 (Pubitemid 23179393)
44. Elisei R, Romei C, Cosci B, Agate L, Bottici V, Molinaro E, Sculli M, Miccoli P, Basolo F, Grasso L, Pacini F, Pinchera A 2007 RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab 92:4725-4729
45. Zedenius J 2008 Is somatic RET mutation a prognostic factor for sporadic medullary thyroid carcinoma? Nat Clin Pract Endocrinol Metab 4:432-433
46. Skinner MA, Moley JA, Dilley WG, Owzar K, Debenedetti MK, Wells Jr SA 2005 Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. N Engl J Med 353:1105-1113
47. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A, Lips CJ, Lombardi G, Mannelli M, Pacini F, Ponder BA, Raue F, Skogseid B, Tamburrano G, Thakker RV, Thompson NW, Tomassetti P, Tonelli F, Wells Jr SA, Marx SJ 2001 Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86:5658-5671
48. Michiels FM, Chappuis S, Caillou B, Pasini A, Talbot M, Monier R, Lenoir GM, Feunteun J, Billaud M 1997 Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation. Proc Natl Acad Sci USA 94:3330-3335
49. Acton DS, Velthuyzen D, Lips CJ, Höppener JW 2000 Multiple endocrine neoplasia type 2B mutation in human RET oncogene induces medullary thyroid carcinoma in transgenic mice. Oncogene 19:3121-3125
50. Cuccuru G, Lanzi C, Cassinelli G, Pratesi G, Tortoreto M, Petrangolini G, Seregni E, Martinetti A, Laccabue D, Zanchi C, Zunino F 2004 Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma. J Natl Cancer Inst 96:1006-1014
51. Drosten M, Hilken G, Böckmann M, Rödicker F, Mise N, Cranston AN, Dahmen U, Ponder BA, Pützer BM 2004 Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma. J Natl Cancer Inst 96:1231-1239
52. Wang W, Johansson HE, Bergholm UI, Westermark KM, Grimelius LE 1997 Expression of c-Myc, TGF-α and EGF-receptor in sporadic medullary thyroid carcinoma. Acta Oncol 36:407-411
53. Croyle M, Akeno N, Knauf JA, Fabbro D, Chen X, Baumgartner JE, Lane HA, Fagin JA 2008 RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR. Cancer Res 68:4183-4191
54. Papotti M, Olivero M, Volante M, Negro F, Prat M, Comoglio PM, DiRenzo MF 2000 Expression of hepatocyte growth factor (HGF) and its receptor (MET) in medullary carcinoma of the thyroid. Endocr Pathol 11:19-30
55. Ezzat S, Huang P, Dackiw A, Asa SL 2005 Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth. Clin Cancer Res 11:1336-1341
56. Cohen MS, Hussain HB, Moley JF 2002 Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors. Surgery 132:960-966; discussion 966-967
57. Skinner MA, Safford SD, Freemerman AJ 2003 RET tyrosine kinase and medullary thyroid cells are unaffected by clinical doses of STI571. Anticancer Res 23:3601-3606
58. de Groot JW, Zonnenberg BA, van Ufford-Mannesse PQ, de Vries MM, Links TP, Lips CJ, Voest EE 2007 A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab 92:3466-3469
59. Frank-Raue K, Fabel M, Delorme S, Haberkorn U, Raue F 2007 Efficacy of imatinib mesylate in advanced medullary thyroid carcinoma. Eur J Endocrinol 157:215-220
60. Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, Ryan AJ, Fontanini G, Fusco A, Santoro M 2002 ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 62:7284-7290
61. Wells S, You YN, Lakhani V, Hou J, Langmuir P, Headley D, Skinner M, Morse M, Burch W, Schlumberger M, A phase II trial of ZD6474 in patients with hereditary metastatic medullary thyroid cancer. Proc of the 42nd Annual Meeting of American Society of Clinical Oncology, 2006, Atlanta, GA (Abstract 5533)
62. Wells SA, Gosnell JE, Gagel RF, Moley JF, Pfister DG, Sosa JA, Skinner M, Krebs A, Hou J, Schlumberger M, Vandetanib in metastatic hereditary medullary thyroid cancer: follow-up results of an open-label phase II trial. Proc of the 43rd Annual Meeting of American Society of Clinical Oncology, 2007, Chicago, IL (Abstract 6018)
63. Fox E, Widemann BC, Whitcomb PO, Aikin A, Dombi E, Lodish M, Stratakis CA, Steinberg S, Wells Jr SA, Balis FM, Phase I/II trial of vandetanib in children and adolescents with hereditary medullary thyroid carcinoma. Proc of the 45th Annual Meeting of American Society of Clinical Oncology, 2009, Orlando, FL (Abstract 10014)
64. Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG, Locati LD, Jarzab B, Pacini F, Daumerie C, Droz JP, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Sherman SI 2009 Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 27:3794-3801
65. Lyons JF, Wilhelm S, Hibner B, Bollag G 2001 Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 8:219-225
66. Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM, Santoro M 2006 BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 98:326-334
67. Lam ET, Ringel MD, Kloos RT, Collamore M, Arbogast D, Liang J, Hall N, Knopp MV, Wright J, Shah MH, Antitumor activity of sorafenib in patients with metastatic medullary thyroid carcinoma. Proc of 100th Annual Meeting of the American Association for Cancer Research, 2009, Denver, CO (Abstract 4513)
68. Hong D, Ye L, Gagel R, Chintala L, El Naggar AK, Wright J, Kurzrock R 2008 Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib. Mol Cancer Ther 7:1001-1006
69. Salgia R, Sherman S, Hong DS, Ng CS, Frye J, Janisch L, Ratain MJ, Kurzrock R, A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC). Proc of the 43rd Annual Meeting of American Society of Clinical Oncology, 2007, Chicago, IL (Abstracts 3522)
70. Hamatani K, Eguchi H, Ito R, Mukai M, Takahashi K, Taga M, Imai K, Cologne J, Soda M, Arihiro K, Fujihara M, Abe K, Hayashi T, Nakashima M, Sekine I, Yasui W, Hayashi Y, Nakachi K 2008 RET/PTC rearrangements preferentially occurred in papillary thyroid cancer among atomic bomb survivors exposed to high radiation dose. Cancer Res 68:7176-7182
71. Nikiforov YE, Rowland JM, Bove KE, Monforte-Munoz H, Fagin JA 1997 Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res 57:1690-1694
72. Williams D 2002 Cancer after nuclear fallout: lessons from the Chernobyl accident. Nat Rev Cancer 2:543-549
73. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA 2003 High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454-1457
74. Xing M, Vasko V, Tallini G, Larin A, Wu G, Udelsman R, Ringel MD, Ladenson PW, Sidransky D 2004 BRAF T1796A transversion mutation in various thyroid neoplasms. J Clin Endocrinol Metab 89:1365-1368
75. Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, Giannini R, Romei C, Miccoli P, Pinchera A, Basolo F 2008 BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab 93:3943-3949
76. Trovisco V, Soares P, Preto A, de Castro IV, Lima J, Castro P, Máximo V, Botelho T, Moreira S, Meireles AM, Magalhães J, Abrosimov A, Cameselle-Teijeiro J, Sobrinho-Simões M 2005 Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch 446:589-595
77. Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, Janakiraman M, Solit D, Knauf JA, Tuttle RM, Ghossein RA, Fagin JA 2009 Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res 69:4885-4893
78. Bongarzone I, Fugazzola L, Vigneri P, Mariani L, Mondellini P, Pacini F, Basolo F, Pinchera A, Pilotti S, Pierotti MA 1996 Age-related activation of the tyrosine kinase receptor protooncogenes RET and NTRK1 in papillary thyroid carcinoma. J Clin Endocrinol Metab 81:2006-2009
79. Bongarzone I, Vigneri P, Mariani L, Collini P, Pilotti S, Pierotti MA 1998 RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinicopathological features. Clin Cancer Res 4:223-228 (Pubitemid 28062900)
80. Gimm O, Greco A, Hoang-Vu C, Dralle H, Pierotti MA, Eng C 1999 Mutation analysis reveals novel sequence variants in NTRK1 in sporadic human medullary thyroid carcinoma. J Clin Endocrinol Metab 84:2784-2787 (Pubitemid 30642013)
81. Brzeziañska E, Pastuszak-Lewandoska D, Lewiñski A 2007 Rearrangements of NTRK1 oncogene in papillary thyroid carcinoma. Neuro Endocrinol Lett 28:221-229
82. Suarez HG, du Villard JA, Severino M, Caillou B, Schlumberger M, Tubiana M, Parmentier C, Monier R 1990 Presence of mutations in all three ras genes in human thyroid tumors. Oncogene 5:565-570 (Pubitemid 20137069)
83. Manenti G, Pilotti S, Re FC, Della Porta G, Pierotti MA 1994 Selective activation of ras oncogenes in follicular and undifferentiated thyroid carcinomas. Eur J Cancer 30A: 987-993
84. Basolo F, Pisaturo F, Pollina LE, Fontanini G, Elisei R, Molinaro E, Iacconi P, Miccoli P, Pacini F 2000 N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression. Thyroid 10:19-23
85. Santarpia L, El-Naggar AK, Cote GJ, Myers JN, Sherman SI 2008 Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab 93:278-284
86. Hou P, Liu D, Shan Y, Hu S, Studeman K, Condouris S, Wang Y, Trink A, El-Naggar AK, Tallini G, Vasko V, Xing M 2007 Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res 13:1161-1170
87. Viglietto G, Maglione D, Rambaldi M, Cerutti J, Romano A, Trapasso F, Fedele M, Ippolito P, Chiappetta G, Botti G 1995 Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene 11:1569-1579
88. Katoh R, Miyagi E, Kawaoi A, Hemmi A, Komiyama A, Oyama T, Shibuya M 1999 Expression of vascular endothelial growth factor (VEGF) in human thyroid neoplasms. Hum Pathol 30:891-897 (Pubitemid 29380511)
89. Lewy-Trenda I, Wierzchniewska-£awska A 2002 Expression of vascular endothelial growth factor (VEGF) in human thyroid tumors. Pol J Pathol 53:129-132 (Pubitemid 35278474)
90. Pasieka Z, Stepieñ H, Komorowski J, Kołomecki K, Kuzdak K 2003 Evaluation of the levels of bFGF, VEGF, sICAM-1, and sVCAM-1 in serum of patients with thyroid cancer. Recent Results Cancer Res 162:189-194
91. Vieira JM, Santos SC, Espadinha C, Correia I, Vag T, Casalou C, Cavaco BM, Catarino AL, Dias S, Leite V 2005 Expression of vascular endothelial growth factor (VEGF) and its receptors in thyroid carcinomas of follicular origin: a potential autocrine loop. Eur J Endocrinol 153:701-709
92. Yasuoka H, Nakamura Y, Zuo H, Tang W, Takamura Y, Miyauchi A, Nakamura M, Mori I, Kakudo K 2005 VEGF-D expression and lymph vessels play an important role for lymph node metastasis in papillary thyroid carcinoma. Mod Pathol 18:1127-1133
93. Belletti B, Ferraro P, Arra C, Baldassarre G, Bruni P, Staibano S, De Rosa G, Salvatore G, Fusco A, Persico MG, Viglietto G 1999 Modulation of in vivo growth of thyroid tumor-derived cell lines by sense and antisense vascular endothelial growth factor gene. Oncogene 18:4860-4869
94. Bauer AJ, Terrell R, Doniparthi NK, Patel A, Tuttle RM, Saji M, Ringel MD, Francis GL 2002 Vascular endothelial growth factor monoclonal antibody inhibits growth of anaplastic thyroid cancer xenografts in nude mice. Thyroid 12:953-961 (Pubitemid 35404129)
95. Hsiao PJ, Lu MY, Chiang FY, Shin SJ, Tai YD, Juo SH 2007 Vascular endothelial growth factor gene polymorphisms in thyroid cancer. J Endocrinol 195:265-270 (Pubitemid 350143106)
96. Tufro A, Teichman J, Banu N, Villegas G 2007 Crosstalk between VEGF-A/VEGFR2 and GDNF/RET signaling pathways. Biochem Biophys Res Commun 358:410-416 (Pubitemid 46766597)
97. Inoue M, Hager JH, Ferrara N, Gerber HP, Hanahan D 2002 VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic β cell carcinogenesis. Cancer Cell 1:193-202 (Pubitemid 41039165)
98. Gorgoulis V, Aninos D, Priftis C, Evagelopoulou C, Karameris A, Kanavaros P, Spandidos DA 1992 Expression of epidermal growth factor, transforming growth factor-α and epidermal growth factor receptor in thyroid tumors. In Vivo 6:291-296
99. Schiff BA, McMurphy AB, Jasser SA, Younes MN, Doan D, Yigitbasi OG, Kim S, Zhou G, Mandal M, Bekele BN, Holsinger FC, Sherman SI, Yeung SC, El-Naggar AK, Myers JN 2004 Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res 10:8594-8602
100. Murakawa T, Tsuda H, Tanimoto T, Tanabe T, Kitahara S, Matsubara O 2005 Expression of KIT, EGFR, HER-2 and tyrosine phosphorylation in undifferentiated thyroid carcinoma: implication for a new therapeutic approach. Pathol Int 55:757-765
101. Mitsiades CS, Kotoula V, Poulaki V, Sozopoulos E, Negri J, Charalambous E, Fanourakis G, Voutsinas G, Tseleni-Balafouta S, Mitsiades N 2006 Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis. J Clin Endocrinol Metab 91:3662-3666
102. Hoelting T, Siperstein AE, Clark OH, Duh QY 1994 Epidermal growth factor enhances proliferation, migration, and invasion of follicular and papillary thyroid cancer in vitro and in vivo. J Clin Endocrinol Metab 79:401-408
103. Lee DH, Lee GK, Kong SY, Kook MC, Yang SK, Park SY, Park SH, Keam B, Park do J, Cho BY, Kim SW, Chung KW, Lee ES, Kim SW 2007 Epidermal growth factor receptor status in anaplastic thyroid carcinoma. J Clin Pathol 60:881-884
104. Masago K, Asato R, Fujita S, Hirano S, Tamura Y, Kanda T, Mio T, Katakami N, Mishima M, Ito J 2009 Epidermal growth factor receptor gene mutations in papillary thyroid carcinoma. Int J Cancer 124:2744-2749
105. Scarpino S, Cancellario d'Alena F, Di Napoli A, Pasquini A, Marzullo A, Ruco LP 2004 Increased expression of Met protein is associated with up-regulation of hypoxia inducible factor-1 (HIF-1) in tumour cells in papillary carcinoma of the thyroid. J Pathol 202:352-358
106. Chakravarty G, Santillan AA, Galer C, Adams HP, El-Naggar AK, Jasser SA, Mohsin S, Mondal D, Clayman GL, Myers JN 2009 Phosphorylated insulin like growth factor-I receptor expression and its clinico-pathological significance in histological subtypes of human thyroid cancer. Exp Biol Med Maywood 234:372-386
107. St Bernard R, Zheng L, Liu W, Winer D, Asa SL, Ezzat S 2005 Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. Endocrinology 146:1145-1153
108. Kondo T, Zheng L, Liu W, Kurebayashi J, Asa SL, Ezzat S 2007 Epigenetically controlled fibroblast growth factor receptor 2 signaling imposes on the RAS/BRAF/mitogen-activated protein kinase pathway to modulate thyroid cancer progression. Cancer Res 67:5461-5470
109. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ 2008 Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 359:31-42
110. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB 2008 Axitinib is an active treatment for all histological subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 26:4708-4713
111. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, Brose MS 2008 Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 26:4714-4719
112. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely Jr PE, Vasko VV, Saji M, Rittenberry J, Wei L, Arbogast D, Collamore M, Wright JJ, Grever M, Shah MH 2009 Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 27:1675-1684
113. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, Bremer R, Gillette S, Kong J, Haass NK, Sproesser K, Li L, Smalley KS, Fong D, Zhu YL, Marimuthu A, Nguyen H, Lam B, Liu J, Cheung I, Rice J, Suzuki Y, Luu C, Settachatgul C, Shellooe R, Cantwell J, Kim SH, Schlessinger J, Zhang KY, West BL, Powell B, Habets G, Zhang C, Ibrahim PN, Hirth P, Artis DR, Herlyn M, Bollag G 2008 Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 105:3041-3046
114. Packer LM, East P, Reis-Filho JS, Marais R 2009 Identification of direct transcriptional targets of BRAF/MEK signalling in melanoma. Pigment Cell Melanoma Res 22:785-798
115. Pennell NA, Daniels GH, Haddad RI, Ross DS, Evans T, Wirth LJ, Fidias PH, Temel JS, Gurubhagavatula S, Heist RS, Clark JR, Lynch TJ 2008 A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid 18:317-323
116. Nappi TC, Salerno P, Zitzelsberger H, Carlomagno F, Salvatore G, Santoro M 2009 Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma. Cancer Res 69:1916-1923
117. Libertini S, Iacuzzo I, Perruolo G, Scala S, Ieranò C, Franco R, Hallden G, Portella G 2008 Bevacizumab increases viral distribution in human anaplastic thyroid carcinoma xenografts and enhances the effects of E1A-defective adenovirus dl922-947. Clin Cancer Res 14:6505-6514
118. Wang Z, Chakravarty G, Kim S, Yazici YD, Younes MN, Jasser SA, Santillan AA, Bucana CD, El-Naggar AK, Myers JN 2006 Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma. Clin Cancer Res 12:4755-4765
119. Kim S, Prichard CN, Younes MN, Yazici YD, Jasser SA, Bekele BN, Myers JN 2006 Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Clin Cancer Res 12:600-607 (Pubitemid 43166155)
120. Srirangalingam U, Khoo B, Walker L, MacDonald F, Skelly RH, George E, Spooner D, Johnston LB, Monson JP, Grossman AB, Drake WM, Akker SA, Pollard PJ, Plowman N, Avril N, Berney DM, Burrin JM, Reznek RH, Kumar VK, Maher ER, Chew SL 2009 Contrasting clinical manifestations of SDHB and VHL associated chromaffin tumours. Endocr Relat Cancer 16:515-525
121. Gimenez-Roqueplo AP, Favier J, Rustin P, Rieubland C, Crespin M, Nau V, Khau Van Kien P, Corvol P, Plouin PF, Jeunemaitre X 2003 Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res 63:5615-5621
122. Scholz T, Eisenhofer G, Pacak K, Dralle H, Lehnert H 2007 Clinical review: current treatment of malignant pheochromocytoma. J Clin Endocrinol Metab 92:1217-1225
123. Huang H, Abraham J, Hung E, Averbuch S, Merino M, Steinberg SM, Pacak K, Fojo T 2008 Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer 113:2020-2028
124. Sisson JC 2002 Radiopharmaceutical treatment of pheochromocytomas. Ann NY Acad Sci 970:54-60
125. Eisenhofer G, Bornstein SR, Brouwers FM, Cheung NK, Dahia PL, de Krijger
126. Yeh IT, Lenci RE, Qin Y, Buddavarapu K, Ligon AH, Leteurtre E, Do Cao C, Cardot-Bauters C, Pigny P, Dahia PL 2008 A germline mutation of the KIF1B β gene on 1p36 in a family with neural and nonneural tumors. Hum Genet 124:279-285
127. Lisztwan J, Imbert G, Wirbelauer C, Gstaiger M, Krek W 1999 The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev 13:1822-1833
128. Pollard PJ, Brière JJ, Alam NA, Barwell J, Barclay E, Wortham NC, Hunt T, Mitchell M, Olpin S, Moat SJ, Hargreaves IP, Heales SJ, Chung YL, Griffiths JR, Dalgleish A, McGrath JA, Gleeson MJ, Hodgson SV, Poulsom R, Rustin P, Tomlinson IP 2005 Accumulation of Krebs cycle intermediates and over-expression of HIF1α in tumours which result from germline FH and SDH mutations. Hum Mol Genet 14:2231-2239
129. Dahia PL 2006 Transcription association of VHL and SDHmutations link hypoxia and oxidoreductase signals in pheochromocytomas. Ann NY Acad Sci 1073:208-220
130. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM 2007 Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134
131. Salmenkivi K, HeikkiläP, Liu J, Haglund C, Arola J 2003 VEGF in 105 pheochromocytomas: enhanced expression correlates with malignant outcome. APMIS 111:458-464
132. Pollard PJ, El-Bahrawy M, Poulsom R, Elia G, Killick P, Kelly G, Hunt T, Jeffery R, Seedhar P, Barwell J, Latif F, Gleeson MJ, Hodgson SV, Stamp GW, Tomlinson IP, Maher ER 2006 Expression of HIF-1α, HIF-2α (EPAS1), and their target genes in paraganglioma and pheochromocytoma with VHL and SDH mutations. J Clin Endocrinol Metab 91:4593-4598
133. Joshua AM, Ezzat S, Asa SL, Evans A, Broom R, Freeman M, Knox JJ 2009 Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma. J Clin Endocrinol Metab 94:5-9
134. Jimenez C, Cabanillas ME, Santarpia L, Jonasch E, Kyle KL, Lano EA, Matin SF, Nunez RF, Perrier ND, Phan A, Rich TA, Shah B, Williams MD, Waguespack SG 2009 Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. J Clin Endocrinol Metab 94:386-391
135. Hahn NM, Reckova M, Cheng L, Baldridge LA, Cummings OW, Sweeney CJ 2009 Patient with malignant paraganglioma responding to the multikinase inhibitor sunitinib malate. J Clin Oncol 27:460-463
136. Park KS, Lee JL, Ahn H, Koh JM, Park I, Choi JS, Kim YR, Park TS, Ahn JH, Lee DH, Kim TW, Lee JS 2009 Sunitinib, a novel therapy for anthracycline- and cisplatin-refractory malignant pheochromocytoma. Jpn J Clin Oncol 39:327-331
137. Gao X, Zhang Y, Arrazola P, Hino O, Kobayashi T, Yeung RS, Ru B, Pan D 2002 Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat Cell Biol 4:699-704
138. Inoki K, Li Y, Zhu T, Wu J, Guan KL 2002 TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4:648-657 (Pubitemid 34993700)
139. Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin Jr WG 2003 TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 4:147-158 (Pubitemid 37045363)
140. Yao JC 2007 Neuroendocrine tumors. Molecular targeted therapy for carcinoid and islet-cell carcinoma. Best Pract Res Clin Endocrinol Metab 21:163-172
141. Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li JZ, Baum CM, Fuchs CS 2008 Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 26:3403-3410
142. Hobday TJ, Holen K, Donehower R, Camoriano J, Kim G, Picus J, Philip P, Lloyd R, Mahoney M, Erlichman C, A phase II trial of gefitinib in patients (pts) with progressive metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study. Proc of the 42nd Annual Meeting of American Society of Clinical Oncology, 2006, Atlanta, GA (Abstract 4043)
143. Hobday TJ, Rubin J, Holen K, Picus J, Donehower R, Marschke R, Maples W, Lloyd R, Mahoney M, Erlichman C, MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study. Proc of the 43nd Annual Meeting of American Society of Clinical Oncology, 2007, Chicago, IL (Abstract 4504)
144. Barlaskar FM, Hammer GD 2007 The molecular genetics of adrenocortical carcinoma. Rev Endocr Metab Disord 8:343-348
145. Gicquel C, Bertagna X, Gaston V, Coste J, Louvel A, Baudin E, Bertherat J, Chapuis Y, Duclos JM, Schlumberger M, Plouin PF, Luton JP, Le Bouc Y 2001 Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res 61:6762-6767
146. Gicquel C, Raffin-Sanson ML, Gaston V, Bertagna X, Plouin PF, Schlumberger M, Louvel A, Luton JP, Le Bouc Y 1997 Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors. J Clin Endocrinol Metab 82:2559-2565
147. Giordano TJ, Thomas DG, Kuick R, Lizyness M, Misek DE, Smith AL, Sanders D, Aljundi RT, Gauger PG, Thompson NW, Taylor JM, Hanash SM 2003 Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am J Pathol 162:521-531
148. Weber MM, Fottner C, Schmidt P, Brodowski KM, Gittner K, Lahm H, Engelhardt D, Wolf E 1999 Postnatal overexpression of insulin-like growth factor II in transgenic mice is associated with adrenocortical hyperplasia and enhanced steroidogenesis. Endocrinology 140:1537-1543 (Pubitemid 29149219)
149. de Fraipont F, El Atifi M, Cherradi N, Le Moigne G, Defaye G, Houlgatte R, Bertherat J, Bertagna X, Plouin PF, Baudin E, Berger F, Gicquel C, Chabre O, Feige JJ 2005 Gene expression profiling ofhumanadrenocortical tumors using complementary deoxyribonucleic acid microarrays identifies several candidate genes as markers of malignancy. J Clin Endocrinol Metab 90:1819-1829
150. West AN, Neale GA, Pounds S, Figueredo BC, Rodriguez Galindo C, Pianovski MA, Oliveira Filho AG, Malkin D, Lalli E, Ribeiro R, Zambetti GP 2007 Gene expression profiling of childhood adrenocortical tumors. Cancer Res 67:600-608
151. Slater EP, Diehl SM, Langer P, Samans B, Ramaswamy A, Zielke A, Bartsch DK 2006 Analysis by cDNA microarrays of gene expression patterns of human adrenocortical tumors. Eur J Endocrinol 154:587-598
152. Barlaskar FM, Spalding AC, Heaton JH, Kuick R, Kim AC, Thomas DG, Giordano TJ, Ben-Josef E, Hammer GD 2009 Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. J Clin Endocrinol Metab 94:204-212
153. Kotoula V, Sozopoulos E, Litsiou H, Fanourakis G, Koletsa T, Voutsinas G, Tseleni-Balafouta S, Mitsiades CS, Wellmann A, Mitsiades N 2009 Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas. Endocr Relat Cancer 16:565-572
154. Crean S, Boyd DM, Sercus B, Lahn M 2009 Safety of multi-targeted kinase inhibitors as monotherapy treatment of cancer: a systematic review of the literature. Curr Drug Saf 4:143-154
155. McNeil C 2006 Two targets, one drug for new EGFR inhibitors. J Natl Cancer Inst 98:1102-1103
156. Chintalgattu V, Patel SS, Khakoo AY 2009 Cardiovascular effects of tyrosine kinase inhibitors used for gastrointestinal stromal tumors. Hematol Oncol Clin North Am 23:97-107, viii-ix
157. Force T, Krause DS, Van Etten RA 2007 Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 7:332-344 (Pubitemid 46652481)
158. KerkeläR, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, Walters B, Shevtsov S, Pesant S, Clubb FJ, Rosenzweig A, Salomon RN, Van Etten RA, Alroy J, Durand JB, Force T 2006 Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12:908-916
159. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, George S, Morgan JA, Harris DM, Ismail NS, Chen JH, Schoen FJ, Van den Abbeele AD, Demetri GD, Force T, Chen MH 2007 Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370:2011-2019 (Pubitemid 350236338)
160. Hasinoff BB, Patel D, O'Hara KA 2008 Mechanisms of myocyte cytotoxicity induced by the multiple receptor tyrosine kinase inhibitor sunitinib. Mol Pharmacol 74:1722-1728
161. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, Faraoni R, Floyd M, Hunt JP, Lockhart DJ, Milanov ZV, Morrison MJ, Pallares G, Patel HK, Pritchard S, Wodicka LM, Zarrinkar PP 2008 A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26:127-132
162. Shiojima I, Sato K, Izumiya Y, Schiekofer S, Ito M, Liao R, Colucci WS, Walsh K2005 Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 115:2108-2118
163. Strevel EL, Ing DJ, Siu LL 2007 Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol 25:3362-3371
164. Maklad A, Nicolai JR, Bichsel KJ, Evenson JE, Lee TC, Threadgill DW, Hansen LA 2009 The EGFR is required for proper innervation to the skin. J Invest Dermatol 129:690-698
165. Hammond-Thelin LA 2008 Cutaneous reactions related to systemic immunomodulators and targeted therapeutics. Dermatol Clin 26:121-159, ix
166. Li T, Perez-Soler R 2009 Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol 4:107-119
167. Lynch Jr TJ, Kim ES, Eaby B, Garey J, West DP, Lacouture ME 2007 Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 12:610-621 (Pubitemid 350012125)
168. Perez-Soler R, Zou Y, Li T, Tornos C, Ling Y, Topical vitamin K3 (Vit K3, Menadione) prevents erlotinib and cetuximab-induced EGFR inhibition in the skin. Proc of the 42nd Annual Meeting of American Society of Clinical Oncology, 2006, Atlanta, GA (Abstract 3036)
169. O'Mahony F, Toumi F, Mroz MS, Ferguson G, Keely SJ 2008 Induction of Na+/K+/2Cl- cotransporter expression mediates chronic potentiation of intestinal epithelial Cl- secretion by EGF. Am J Physiol Cell Physiol 294:C1362-C1370
170. Santarpia L, Ye L, Gagel RF 2009 Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma. J Intern Med 266:99-113
171. Cerrato A, De Falco V, Santoro M 2009 Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets. J Mol Endocrinol 43:143-155
172. Papotti M, Kumar U, Volante M, Pecchioni C, Patel YC 2001 Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid. Clin Endocrinol (Oxf) 54:641-649 (Pubitemid 34208908)
173. Mato E, Matías-Guiu X, Chico A, Webb SM, Cabezas R, Berná L, De Leiva A 1998 Somatostatin and somatostatin receptor subtype gene expression in medullary thyroid carcinoma. J Clin Endocrinol Metab 83:2417-2420 (Pubitemid 28503040)
174. Vainas I, Koussis Ch, Pazaitou-Panayiotou K, Drimonitis A, Chrisoulidou A, Iakovou I, Boudina M, Kaprara A, Maladaki A 2004 Somatostatin receptor expression in vivo and response to somatostatin analog therapy with or without other antineoplastic treatments in advanced medullary thyroid carcinoma. J Exp Clin Cancer Res 23:549-559
175. Kreisl TN, Lassman AB, Mischel PS, Rosen N, Scher HI, Teruya-Feldstein J, Shaffer D, Lis E, Abrey LE 2009 A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). J Neurooncol 92:99-105
176. Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, Jacobs C, Mares JE, Landgraf AN, Rashid A, Meric-Bernstam F 2008 Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 26:4311-4318
177. Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L, Martin N, Becker D, Bergsneider M, Lai A, Green R, Oglesby T, Koleto M, Trent J, Horvath S, Mischel PS, Mellinghoff IK, Sawyers CL 2008 Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 5:e8
178. 2008 Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-1068
179. Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R, Stegh AH, Bradner JE, Ligon KL, Brennan C, Chin L, DePinho RA 2007 Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318:287-290
180. Deininger M, Buchdunger E, Druker BJ 2005 The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105:2640-2653 (Pubitemid 40446252)
181. Hennequin LF, Stokes ES, Thomas AP, Johnstone C, Plé PA, Ogilvie DJ, Dukes M, Wedge SR, Kendrew J, Curwen JO 2002 Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J Med Chem 45:1300-1312
182. Polverino A, Coxon A, Starnes C, Diaz Z, DeMelfi T, Wang L, Bready J, Estrada J, Cattley R, Kaufman S, Chen D, Gan Y, Kumar G, Meyer J, Neervannan S, Alva G, Talvenheimo J, Montestruque S, Tasker A, Patel V, Radinsky R, Kendall R 2006 AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 66:8715-8721
183. Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY, McTigue MA, Murray BW, Kania RS, O'Connor P, Shalinsky DR, Bender SL 2008 Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 14:7272-7283
184. Plaza-Menacho I, Mologni L, Sala E, Gambacorti-Passerini C, Magee AI, Links TP, Hofstra RM, Barford D, Isacke CM 2007 Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RETlysosomal degradation independent of proteasomal targeting. J Biol Chem 282:29230-29240
185. Brehmer D, Greff Z, Godl K, Blencke S, Kurtenbach A, Weber M, Müller S, Klebl B, Cotten M, Kéri G, Wissing J, Daub H 2005 Cellular targets of gefitinib. Cancer Res 65:379-382
186. Roskoski Jr R 2007 Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun 356:323-328
187. Srirangalingam U, Khoo B, Walker L, MacDonald F, Skelly RH, George E, Spooner D, Johnston LB, Monson JP, Grossman AB, Drake WM, Akker SA, Pollard PJ, Plowman N, Avril N, Berney DM, Burrin JM, Reznek RH, Kumar VK, Maher ER, Chew SL 2009 Contrasting clinical manifestations of SDHB and VHL associated chromaffin tumours. Endocr Relat Cancer 16:515-525
188. Gimenez-Roqueplo AP, Favier J, Rustin P, Rieubland C, Crespin M, Nau V, Khau Van Kien P, Corvol P, Plouin PF, Jeunemaitre X 2003 Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res 63:5615-5621
189. Scholz T, Eisenhofer G, Pacak K, Dralle H, Lehnert H 2007 Clinical review: current treatment of malignant pheochromocytoma. J Clin Endocrinol Metab 92:1217-1225
190. Huang H, Abraham J, Hung E, Averbuch S, Merino M, Steinberg SM, Pacak K, Fojo T 2008 Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer 113:2020-2028
191. Sisson JC 2002 Radiopharmaceutical treatment of pheochromocytomas. Ann NY Acad Sci 970:54-60
192. Eisenhofer G, Bornstein SR, Brouwers FM, Cheung NK, Dahia PL, de Krijger RR, Giordano TJ, Greene LA, Goldstein DS, Lehnert H, Manger WM, Maris JM, Neumann HP, Pacak K, Shulkin BL, Smith DI, Tischler AS, Young Jr WF 2004 Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer 11:423-436
193. Yeh IT, Lenci RE, Qin Y, Buddavarapu K, Ligon AH, Leteurtre E, Do Cao C, Cardot-Bauters C, Pigny P, Dahia PL 2008 A germline mutation of the KIF1B β gene on 1p36 in a family with neural and nonneural tumors. Hum Genet 124:279-285
194. Lisztwan J, Imbert G, Wirbelauer C, Gstaiger M, Krek W 1999 The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev 13:1822-1833
195. Pollard PJ, Brière JJ, Alam NA, Barwell J, Barclay E, Wortham NC, Hunt T, Mitchell M, Olpin S, Moat SJ, Hargreaves IP, Heales SJ, Chung YL, Griffiths JR, Dalgleish A, McGrath JA, Gleeson MJ, Hodgson SV, Poulsom R, Rustin P, Tomlinson IP 2005 Accumulation of Krebs cycle intermediates and over-expression of HIF1α in tumours which result from germline FH and SDH mutations. Hum Mol Genet 14:2231-2239
196. Dahia PL 2006 Transcription association of VHL and SDHmutations link hypoxia and oxidoreductase signals in pheochromocytomas. Ann NY Acad Sci 1073:208-220
197. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM 2007 Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134
198. Salmenkivi K, HeikkiläP, Liu J, Haglund C, Arola J 2003 VEGF in 105 pheochromocytomas: enhanced expression correlates with malignant outcome. APMIS 111:458-464
199. Pollard PJ, El-Bahrawy M, Poulsom R, Elia G, Killick P, Kelly G, Hunt T, Jeffery R, Seedhar P, Barwell J, Latif F, Gleeson MJ, Hodgson SV, Stamp GW, Tomlinson IP, Maher ER 2006 Expression of HIF-1α, HIF-2α (EPAS1), and their target genes in paraganglioma and pheochromocytoma with VHL and SDH mutations. J Clin Endocrinol Metab 91:4593-4598
200. Joshua AM, Ezzat S, Asa SL, Evans A, Broom R, Freeman M, Knox JJ 2009 Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma. J Clin Endocrinol Metab 94:5-9
201. Jimenez C, Cabanillas ME, Santarpia L, Jonasch E, Kyle KL, Lano EA, Matin SF, Nunez RF, Perrier ND, Phan A, Rich TA, Shah B, Williams MD, Waguespack SG 2009 Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. J Clin Endocrinol Metab 94:386-391
202. Hahn NM, Reckova M, Cheng L, Baldridge LA, Cummings OW, Sweeney CJ 2009 Patient with malignant paraganglioma responding to the multikinase inhibitor sunitinib malate. J Clin Oncol 27:460-463
203. Park KS, Lee JL, Ahn H, Koh JM, Park I, Choi JS, Kim YR, Park TS, Ahn JH, Lee DH, Kim TW, Lee JS 2009 Sunitinib, a novel therapy for anthracycline- and cisplatin-refractory malignant pheochromocytoma. Jpn J Clin Oncol 39:327-331
204. Gao X, Zhang Y, Arrazola P, Hino O, Kobayashi T, Yeung RS, Ru B, Pan D 2002 Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat Cell Biol 4:699-704
205. Inoki K, Li Y, Zhu T, Wu J, Guan KL 2002 TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4:648-657 (Pubitemid 34993700)
206. Brugarolas JB, Vazquez F, Reddy A, Sellers WR, Kaelin Jr WG 2003 TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 4:147-158 (Pubitemid 37045363)
207. Yao JC 2007 Neuroendocrine tumors. Molecular targeted therapy for carcinoid and islet-cell carcinoma. Best Pract Res Clin Endocrinol Metab 21:163-172
208. Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li JZ, Baum CM, Fuchs CS 2008 Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 26:3403-3410
209. Hobday TJ, Holen K, Donehower R, Camoriano J, Kim G, Picus J, Philip P, Lloyd R, Mahoney M, Erlichman C, A phase II trial of gefitinib in patients (pts) with progressive metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study. Proc of the 42nd Annual Meeting of American Society of Clinical Oncology, 2006, Atlanta, GA (Abstract 4043)
210. Hobday TJ, Rubin J, Holen K, Picus J, Donehower R, Marschke R, Maples W, Lloyd R, Mahoney M, Erlichman C, MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study. Proc of the 43nd Annual Meeting of American Society of Clinical Oncology, 2007, Chicago, IL (Abstract 4504)
211. Barlaskar FM, Hammer GD 2007 The molecular genetics of adrenocortical carcinoma. Rev Endocr Metab Disord 8:343-348
212. Gicquel C, Bertagna X, Gaston V, Coste J, Louvel A, Baudin E, Bertherat J, Chapuis Y, Duclos JM, Schlumberger M, Plouin PF, Luton JP, Le Bouc Y 2001 Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res 61:6762-6767
213. Gicquel C, Raffin-Sanson ML, Gaston V, Bertagna X, Plouin PF, Schlumberger M, Louvel A, Luton JP, Le Bouc Y 1997 Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors. J Clin Endocrinol Metab 82:2559-2565
214. Giordano TJ, Thomas DG, Kuick R, Lizyness M, Misek DE, Smith AL, Sanders D, Aljundi RT, Gauger PG, Thompson NW, Taylor JM, Hanash SM 2003 Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am J Pathol 162:521-531
215. Weber MM, Fottner C, Schmidt P, Brodowski KM, Gittner K, Lahm H, Engelhardt D, Wolf E 1999 Postnatal overexpression of insulin-like growth factor II in transgenic mice is associated with adrenocortical hyperplasia and enhanced steroidogenesis. Endocrinology 140:1537-1543 (Pubitemid 29149219)
216. de Fraipont F, El Atifi M, Cherradi N, Le Moigne G, Defaye G, Houlgatte R, Bertherat J, Bertagna X, Plouin PF, Baudin E, Berger F, Gicquel C, Chabre O, Feige JJ 2005 Gene expression profiling ofhumanadrenocortical tumors using complementary deoxyribonucleic acid microarrays identifies several candidate genes as markers of malignancy. J Clin Endocrinol Metab 90:1819-1829
217. West AN, Neale GA, Pounds S, Figueredo BC, Rodriguez Galindo C, Pianovski MA, Oliveira Filho AG, Malkin D, Lalli E, Ribeiro R, Zambetti GP 2007 Gene expression profiling of childhood adrenocortical tumors. Cancer Res 67:600-608
218. Slater EP, Diehl SM, Langer P, Samans B, Ramaswamy A, Zielke A, Bartsch DK 2006 Analysis by cDNA microarrays of gene expression patterns of human adrenocortical tumors. Eur J Endocrinol 154:587-598
219. Barlaskar FM, Spalding AC, Heaton JH, Kuick R, Kim AC, Thomas DG, Giordano TJ, Ben-Josef E, Hammer GD 2009 Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. J Clin Endocrinol Metab 94:204-212
220. Kotoula V, Sozopoulos E, Litsiou H, Fanourakis G, Koletsa T, Voutsinas G, Tseleni-Balafouta S, Mitsiades CS, Wellmann A, Mitsiades N 2009 Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas. Endocr Relat Cancer 16:565-572
221. Crean S, Boyd DM, Sercus B, Lahn M 2009 Safety of multi-targeted kinase inhibitors as monotherapy treatment of cancer: a systematic review of the literature. Curr Drug Saf 4:143-154
222. McNeil C 2006 Two targets, one drug for new EGFR inhibitors. J Natl Cancer Inst 98:1102-1103
223. Chintalgattu V, Patel SS, Khakoo AY 2009 Cardiovascular effects of tyrosine kinase inhibitors used for gastrointestinal stromal tumors. Hematol Oncol Clin North Am 23:97-107, viii-ix
224. Force T, Krause DS, Van Etten RA 2007 Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 7:332-344 (Pubitemid 46652481)
225. KerkeläR, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, Walters B, Shevtsov S, Pesant S, Clubb FJ, Rosenzweig A, Salomon RN, Van Etten RA, Alroy J, Durand JB, Force T 2006 Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12:908-916
226. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, George S, Morgan JA, Harris DM, Ismail NS, Chen JH, Schoen FJ, Van den Abbeele AD, Demetri GD, Force T, Chen MH 2007 Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370:2011-2019 (Pubitemid 350236338)
227. Hasinoff BB, Patel D, O'Hara KA 2008 Mechanisms of myocyte cytotoxicity induced by the multiple receptor tyrosine kinase inhibitor sunitinib. Mol Pharmacol 74:1722-1728
228. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, Faraoni R, Floyd M, Hunt JP, Lockhart DJ, Milanov ZV, Morrison MJ, Pallares G, Patel HK, Pritchard S, Wodicka LM, Zarrinkar PP 2008 A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26:127-132
229. Shiojima I, Sato K, Izumiya Y, Schiekofer S, Ito M, Liao R, Colucci WS, Walsh K2005 Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 115:2108-2118
230. Strevel EL, Ing DJ, Siu LL 2007 Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol 25:3362-3371
231. Maklad A, Nicolai JR, Bichsel KJ, Evenson JE, Lee TC, Threadgill DW, Hansen LA 2009 The EGFR is required for proper innervation to the skin. J Invest Dermatol 129:690-698
232. Hammond-Thelin LA 2008 Cutaneous reactions related to systemic immunomodulators and targeted therapeutics. Dermatol Clin 26:121-159, ix
233. Li T, Perez-Soler R 2009 Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol 4:107-119
234. Lynch Jr TJ, Kim ES, Eaby B, Garey J, West DP, Lacouture ME 2007 Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 12:610-621 (Pubitemid 350012125)
235. Perez-Soler R, Zou Y, Li T, Tornos C, Ling Y, Topical vitamin K3 (Vit K3, Menadione) prevents erlotinib and cetuximab-induced EGFR inhibition in the skin. Proc of the 42nd Annual Meeting of American Society of Clinical Oncology, 2006, Atlanta, GA (Abstract 3036)
236. O'Mahony F, Toumi F, Mroz MS, Ferguson G, Keely SJ 2008 Induction of Na+/K+/2Cl- cotransporter expression mediates chronic potentiation of intestinal epithelial Cl- secretion by EGF. Am J Physiol Cell Physiol 294:C1362-C1370
237. Santarpia L, Ye L, Gagel RF 2009 Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma. J Intern Med 266:99-113
238. Cerrato A, De Falco V, Santoro M 2009 Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets. J Mol Endocrinol 43:143-155
239. Papotti M, Kumar U, Volante M, Pecchioni C, Patel YC 2001 Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid. Clin Endocrinol (Oxf) 54:641-649 (Pubitemid 34208908)
240. Mato E, Matías-Guiu X, Chico A, Webb SM, Cabezas R, Berná L, De Leiva A 1998 Somatostatin and somatostatin receptor subtype gene expression in medullary thyroid carcinoma. J Clin Endocrinol Metab 83:2417-2420 (Pubitemid 28503040)
241. Vainas I, Koussis Ch, Pazaitou-Panayiotou K, Drimonitis A, Chrisoulidou A, Iakovou I, Boudina M, Kaprara A, Maladaki A 2004 Somatostatin receptor expression in vivo and response to somatostatin analog therapy with or without other antineoplastic treatments in advanced medullary thyroid carcinoma. J Exp Clin Cancer Res 23:549-559
242. Kreisl TN, Lassman AB, Mischel PS, Rosen N, Scher HI, Teruya-Feldstein J, Shaffer D, Lis E, Abrey LE 2009 A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM). J Neurooncol 92:99-105
243. Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, Jacobs C, Mares JE, Landgraf AN, Rashid A, Meric-Bernstam F 2008 Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 26:4311-4318
244. Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L, Martin N, Becker D, Bergsneider M, Lai A, Green R, Oglesby T, Koleto M, Trent J, Horvath S, Mischel PS, Mellinghoff IK, Sawyers CL 2008 Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 5:e8
245. 2008 Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-1068
246. Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R, Stegh AH, Bradner JE, Ligon KL, Brennan C, Chin L, DePinho RA 2007 Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318:287-290
247. Deininger M, Buchdunger E, Druker BJ 2005 The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105:2640-2653 (Pubitemid 40446252)
248. Hennequin LF, Stokes ES, Thomas AP, Johnstone C, Plé PA, Ogilvie DJ, Dukes M, Wedge SR, Kendrew J, Curwen JO 2002 Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J Med Chem 45:1300-1312
249. Polverino A, Coxon A, Starnes C, Diaz Z, DeMelfi T, Wang L, Bready J, Estrada J, Cattley R, Kaufman S, Chen D, Gan Y, Kumar G, Meyer J, Neervannan S, Alva G, Talvenheimo J, Montestruque S, Tasker A, Patel V, Radinsky R, Kendall R 2006 AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 66:8715-8721
250. Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY, McTigue MA, Murray BW, Kania RS, O'Connor P, Shalinsky DR, Bender SL 2008 Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 14:7272-7283
251. Plaza-Menacho I, Mologni L, Sala E, Gambacorti-Passerini C, Magee AI, Links TP, Hofstra RM, Barford D, Isacke CM 2007 Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RETlysosomal degradation independent of proteasomal targeting. J Biol Chem 282:29230-29240
252. Brehmer D, Greff Z, Godl K, Blencke S, Kurtenbach A, Weber M, Müller S, Klebl B, Cotten M, Kéri G, Wissing J, Daub H 2005 Cellular targets of gefitinib. Cancer Res 65:379-382
253. Roskoski Jr R 2007 Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun 356:323-328